(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Body Weight D001835 333 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Fibrosis D005355 23 associated lipids
Glioblastoma D005909 27 associated lipids
Glioma D005910 112 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hypergammaglobulinemia D006942 9 associated lipids
Insulin Resistance D007333 99 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Nephritis D009393 19 associated lipids
Neurilemmoma D009442 10 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Llorente-Cortés V et al. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. 1998 Arterioscler. Thromb. Vasc. Biol. pmid:9598832
George J et al. Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. 2004 Arterioscler. Thromb. Vasc. Biol. pmid:14670932
Frenkel J et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. 2002 Arthritis Rheum. pmid:12384940
Corsini A et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. 1993 Atherosclerosis pmid:8216498
Giricz Z et al. Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis. 2003 Basic Res. Cardiol. pmid:12955403
Tanaka H et al. MEKA/phosducin attenuates hydrophobicity of transducin beta gamma subunits without binding to farnesyl moiety. 1996 Biochem. Biophys. Res. Commun. pmid:8687440
Yang L et al. ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways. 2011 Biochem. Biophys. Res. Commun. pmid:21621522
Kamiya Y et al. Metabolites of mating pheromone, rhodotorucine A, by a cells of Rhodosporidium toruloides. 1980 Biochem. Biophys. Res. Commun. pmid:7396935
Keung WM Human liver alcohol dehydrogenases catalyze the oxidation of the intermediary alcohols of the shunt pathway of mevalonate metabolism. 1991 Biochem. Biophys. Res. Commun. pmid:1993065
Castelli A et al. Effect of hydroxy analogs of coenzyme Q on DPNH- and succin-oxidase activities of yeast mitochondria. 1971 Biochem. Biophys. Res. Commun. pmid:4324835
Kamiya Y et al. Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in Rhodosporidium toruloides. 1978 Biochem. Biophys. Res. Commun. pmid:708426
Mizukami Y et al. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. 2001 Biochem. Biophys. Res. Commun. pmid:11594773
Tsuchiya E and Fukui S Binding of rhodotorucine A, a lipopeptidyl mating hormone, to a cells of Rhodosporidium toruloides for induction of sexual differentiation. 1978 Biochem. Biophys. Res. Commun. pmid:743290
Rakhit RD et al. Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury. 2001 Biochem. Biophys. Res. Commun. pmid:11527399
Miquel K et al. Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. 1996 Biochem. Biophys. Res. Commun. pmid:8780704
Raner GM et al. Farnesol as an inhibitor and substrate for rabbit liver microsomal P450 enzymes. 2002 Biochem. Biophys. Res. Commun. pmid:12054554
Krishna G et al. An enzyme-bound intermediate in the conversion of farnesyl pyrophosphate to squalene. 1964 Biochem. Biophys. Res. Commun. pmid:4284347
Crick DC et al. Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells. 1995 Biochem. Biophys. Res. Commun. pmid:7794274
Voziyan PA et al. Mechanism of farnesol cytotoxicity: further evidence for the role of PKC-dependent signal transduction in farnesol-induced apoptotic cell death. 1995 Biochem. Biophys. Res. Commun. pmid:7626062
Fliesler SJ and Keller RK Metabolism of [3H]farnesol to cholesterol and cholesterogenic intermediates in the living rat eye. 1995 Biochem. Biophys. Res. Commun. pmid:7763243

Table of Content